An open randomised phase II study of gemcitabine plus cisplatin +/- concomitant or sequential ZD1839 [gefitinib] in patients with advanced or metastatic transitional cell carcinoma of the urothelium

Trial Profile

An open randomised phase II study of gemcitabine plus cisplatin +/- concomitant or sequential ZD1839 [gefitinib] in patients with advanced or metastatic transitional cell carcinoma of the urothelium

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2016

At a glance

  • Drugs Cisplatin; Gefitinib; Gemcitabine
  • Indications Bladder cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 16 Dec 2007 Status changed from in progress to completed.
    • 01 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top